LevitasBio
PrivateLast Round
Series C
Nov 7, 2022
Total Funding Raised
$61M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
LevitasBio operates in Healthcare & Life Sciences and is based in Hayward, California. Its latest recorded funding round was a Series C round in November 2022.
LevitasBio is a life sciences company that provides a label-free single-cell imaging and profiling platform for purifying cells and nuclei without markers or modifications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LevitasBio Comparables
Compare LevitasBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Deepcell | 84% | |
| NanoCellect Biomedical | 84% | |
| Cell Microsystems | 82% |
For institutional investors. Book with your work email.
LevitasBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 7, 2022 | ||||
| Series B | Jan 6, 2021 | ||||
| Series A | Aug 3, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
LevitasBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Wuhan Thalys Medical Technology | Series B |
| Pavilion Capital | Series C |
| Novalis LifeSciences | Series C |
| Eos | Series C |
| Decheng Capital | Series C, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 51% MoM.
- Nov 7, 2022
$35M round led by Novalis LifeSciences.
For institutional investors. Book with your work email.
LevitasBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about LevitasBio's valuation, stock price, and market status.
Is LevitasBio a public or private company?
LevitasBio is a private company.
What is the current stock price of LevitasBio?
LevitasBio is a private company, so its shares have no public market price. Caplight tracks LevitasBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is LevitasBio worth (valuation)?
Valuation information for LevitasBio is not publicly available.
Can I buy LevitasBio stock?
LevitasBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was LevitasBio's last funding round?
LevitasBio's most recent funding round was Series C on November 7, 2022.
Who are the main investors in LevitasBio?
Key investors in LevitasBio include Novalis LifeSciences, Decheng Capital.
Will LevitasBio IPO soon?
No public IPO plans have been announced for LevitasBio.
How can I track LevitasBio secondary market activity?
Caplight tracks bids, offers, and trades in LevitasBio's shares on secondary markets.